153 related articles for article (PubMed ID: 12048682)
1. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
Jin Z; Guan T; Li S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
[TBL] [Abstract][Full Text] [Related]
2. [Biologic effects of introduction of wild-type p53 cDNA into a human ovarian cancer cell line SKOV-3].
You Z; Guo Y; Cao Z
Zhonghua Fu Chan Ke Za Zhi; 1997 Dec; 32(12):715-7. PubMed ID: 9772432
[TBL] [Abstract][Full Text] [Related]
3. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
4. Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
Aunoble B; Bernard-Gallon D; Bignon YJ
Oncol Rep; 2001; 8(3):663-8. PubMed ID: 11295099
[TBL] [Abstract][Full Text] [Related]
5. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
Lu YM; Zhang SL; Meng LR; Zhao YY
Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
Donninger H; Binder A; Bohm L; Parker MI
Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
[TBL] [Abstract][Full Text] [Related]
8. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].
Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689
[TBL] [Abstract][Full Text] [Related]
9. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
11. [Suppression of insulin-like growth factor-1 receptor by RNA interference inhibits cell growth in vitro and induces chemosensitization of HO8910PM cell to cisplatin].
Gao H; Shi J; Ge SF; DI W
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):45-9. PubMed ID: 18366933
[TBL] [Abstract][Full Text] [Related]
12. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
13. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity.
Smith ML; Kontny HU; Bortnick R; Fornace AJ
Exp Cell Res; 1997 Jan; 230(1):61-8. PubMed ID: 9013707
[TBL] [Abstract][Full Text] [Related]
14. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
[TBL] [Abstract][Full Text] [Related]
16. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
Siddik ZH; Mims B; Lozano G; Thai G
Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
[TBL] [Abstract][Full Text] [Related]
17. [Proliferation inhibition and apoptosis onset in human ovarian carcinoma cell line SKOV3 induced by Genistein].
Li Y; Mi C
Ai Zheng; 2003 Jun; 22(6):586-91. PubMed ID: 12948406
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.
Gatti L; Supino R; Perego P; Pavesi R; Caserini C; Carenini N; Righetti SC; Zuco V; Zunino F
Cell Death Differ; 2002 Dec; 9(12):1352-9. PubMed ID: 12478472
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
20. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]